Business
Jaguar Health Reports Second Quarter 2023 Financial Results
Net revenue increased 36% in Q2 2023 versus Q1 2023Top line results expected late October 2023 for company's phase 3 OnTarget trial of crofelemer for
About this update from Jaguar Health, Inc.
[{"type":"text","content":"Net revenue increased 36% in Q2 2023 versus Q1 2023Top line results expected late October 2023 for company's phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapy-related diarrheaJaguar is supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of short bowel syndrome and microvillus inclusion disease in the EU and Middle East/North Africa regions, with results expected before the end of 2023 and in 2024REMINDER: Jaguar to host investor webcast Monday, August 14th at 8:30 a.m. Eastern regarding Q2 2023 financials and company updates; Click here to register for webcastSAN FRANCISCO, CA / ACCESSWIRE / August 14, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) (\"Jaguar\" or the \"Company\") today reported consolidated second-quarter 2023 financial results and provided Company updates.The combined net revenue for Mytesi® (crofelemer) and the Company's crofelemer prescription product for treatment of chemotherapy-induced diarrhea in dogs, Canalevia®-CA1, which became commercially available in April 2022, was approximately $2.7 million in the second quarter of 2023, representing an increase of 36% compared to prescription product net revenue in the first quarter of 2023, which totaled approximately $2.0 million, and a decrease of approximately 8% over prescription product net revenue in the second quarter of 2022, which totaled approximately $2.9 million. The loss from operations increased by $1.6 million, from $6.4 million in the quarter ended June 30, 2022 to $8.1 million during the same period in 2023.Lisa Conte, Jaguar's president and CEO, said, \"Our paramount near-term clinical activity is our Phase 3 pivotal OnTarget trial of Mytesi for the follow-on indication of the preventative treatment of chemotherapy-induced overactive bowel (CIOB) - which includes symptoms such as chronic debilitating diarrhea, GI urgency, and GI incontinence. We have completed patient enrollment for OnTarget - a key step on our journey to making crofelemer available to treat the neglected comorbidity of CIOB - and top line results from this pivotal study are expected in late October 2023. With success, we expect to expand the indication of Mytesi in 2024.\"Jaguar is supporting investigator-initiated and investigator IND proof-of-concept studies of crofelemer for microvillus inclusio...